Robin Shane Readnour, Director at AN2 Therapeutics, sold ANTX on Sep 3, 2026
Data as of Oct 16
- Traded
- Sep 3, 2026
- Disclosed
- Sep 8, 2026
- Filed
- 5 days after the trade · late
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
ANTX since disclosure
−43.5%
after the sale
Similar stocks (XLV) since disclosure
+5.7%
XLV — its sector index fund
Change in closing price from Sep 8, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLRobin Shane Readnour DirectorANTX AN2 Therapeutics, Inc.$31.9Kdisclosed Sep 8 · filed the same day
- ▼ SELLRobin Shane Readnour DirectorANTX AN2 Therapeutics, Inc.$28.4Kdisclosed Sep 8 · filed the same day
- ▼ SELLRobin Shane Readnour DirectorANTX AN2 Therapeutics, Inc.$19.6Kdisclosed Sep 8 · filed 5 days after the trade · late